Egle Therapeutics
Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, developing novel approaches to modulate regulatory T cell (Treg) activity for cancer and autoimmune diseases. They have developed a proprietary translational platform to identify Treg targets and develop antibody-based candidate drugs. Their lead candidate, EGL-001, is in a Phase I/II clinical trial.
Funding Round:
Funding Amount: €9.3M
Date: 17-Mar-2025
Investors: Bpifrance
Markets: Biotech, Therapeutics, Oncology, Autoimmune Diseases
HQ: Paris, France
Founded: 2020
Website: https://www.egle-tx.com
LinkedIn: https://www.linkedin.com/company/egle-tx
Crunchbase: https://www.crunchbase.com/organization/egle-therapeutics
Leave a Comment
Comments
No comments yet.